Dabigatran etexilate Olpha: Uses, Dosage & Side Effects
Direct oral anticoagulant (DOAC) – reversible direct thrombin inhibitor for stroke prevention and blood clot treatment
Quick facts about Dabigatran etexilate Olpha
Key Takeaways
- Dabigatran etexilate Olpha is a generic direct oral anticoagulant (DOAC) that prevents blood clots by directly and reversibly inhibiting thrombin, the key enzyme that converts fibrinogen to fibrin.
- The RE-LY trial demonstrated that dabigatran 150 mg twice daily was superior to warfarin for stroke prevention in atrial fibrillation, while the 110 mg dose was non-inferior with significantly less major bleeding.
- Unlike factor Xa inhibitors, dabigatran has a specific reversal agent – idarucizumab (Praxbind) – and can also be removed by haemodialysis due to its low protein binding (~35%).
- Renal function monitoring is essential, as approximately 80% of dabigatran is excreted unchanged by the kidneys. Dose adjustments are required for patients with impaired renal function.
- Capsules must be swallowed whole – never opened, crushed, or chewed – as this dramatically increases bioavailability and bleeding risk.
What Is Dabigatran etexilate Olpha and What Is It Used For?
Quick Answer: Dabigatran etexilate Olpha is a direct oral anticoagulant (DOAC) that belongs to the class of direct thrombin inhibitors. It is a generic version of dabigatran etexilate, used to prevent stroke in atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and prevent blood clots after hip or knee replacement surgery.
Dabigatran etexilate Olpha contains the active substance dabigatran etexilate, a prodrug that is rapidly converted to its active form, dabigatran, after oral administration. Dabigatran is a potent, competitive, reversible direct thrombin inhibitor. Thrombin (also known as factor IIa) is a serine protease that plays a central role in the coagulation cascade by converting soluble fibrinogen into insoluble fibrin strands, which form the structural framework of blood clots. By directly inhibiting thrombin, dabigatran effectively prevents the formation of blood clots (thrombi) in both arterial and venous territories.
The originator product, Pradaxa, was developed by Boehringer Ingelheim and was the first direct oral anticoagulant to receive regulatory approval. The European Medicines Agency (EMA) approved dabigatran etexilate in 2008 for venous thromboembolism prevention after orthopaedic surgery, and in 2011 for stroke prevention in atrial fibrillation. The U.S. Food and Drug Administration (FDA) approved it in 2010. Since patent expiry, several generic versions, including Dabigatran etexilate Olpha, have become available, providing the same clinical efficacy and safety profile at a more accessible cost.
Dabigatran etexilate belongs to the broader family of direct oral anticoagulants (DOACs), which also includes the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. However, dabigatran is unique among DOACs as the only direct thrombin inhibitor in the group, giving it a distinct mechanism of action. This differentiation has clinical implications, including the availability of a specific reversal agent (idarucizumab) and the ability to remove the drug by haemodialysis – features not shared by factor Xa inhibitors.
Approved Indications
Dabigatran etexilate Olpha is approved for the following clinical indications, consistent with the originator product Pradaxa:
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) who have one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75, heart failure (NYHA class ≥II), diabetes mellitus, or hypertension.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults, following treatment with a parenteral anticoagulant administered for at least 5 days.
- Prevention of recurrent DVT and PE in adults who have been previously treated.
- Prevention of venous thromboembolism (VTE) in adult patients who have undergone elective hip or knee replacement surgery.
The European Society of Cardiology (ESC) 2024 guidelines recommend DOACs, including dabigatran, as the preferred oral anticoagulants over warfarin for stroke prevention in patients with atrial fibrillation, except in patients with mechanical heart valves or moderate-to-severe mitral stenosis. Dabigatran is also included on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its global importance in anticoagulation therapy.
Mechanism of Action
Dabigatran etexilate is an orally administered prodrug with no pharmacological activity itself. After oral intake, it is rapidly and completely converted to dabigatran by esterase-catalysed hydrolysis in the plasma and liver. Dabigatran is a potent, competitive, reversible direct thrombin inhibitor. It binds to the active site of thrombin (both free and clot-bound) and inhibits thrombin-induced platelet aggregation. This dual mechanism – preventing fibrin formation and reducing thrombin-mediated platelet activation – provides comprehensive antithrombotic activity.
A key pharmacological distinction of dabigatran compared to factor Xa inhibitors is that it inhibits thrombin directly, at the final common step of the coagulation cascade. This means it blocks the conversion of fibrinogen to fibrin regardless of which upstream pathway (intrinsic or extrinsic) activated the cascade. The reversible nature of thrombin binding means that the anticoagulant effect diminishes as dabigatran is cleared from the plasma, primarily through renal excretion.
What Should You Know Before Taking Dabigatran etexilate Olpha?
Quick Answer: Before starting dabigatran, your doctor must assess your kidney function, bleeding risk, and other medications. Dabigatran is contraindicated in severe renal impairment (CrCl <30 mL/min), active clinically significant bleeding, and in patients with prosthetic heart valves. Renal function must be monitored regularly during treatment.
Before prescribing dabigatran etexilate Olpha, your healthcare provider will conduct a comprehensive evaluation of your medical history, current medications, kidney function, and overall health status. Because approximately 80% of dabigatran is excreted unchanged by the kidneys, renal function assessment is of paramount importance – more so than with any other DOAC. Anticoagulant therapy always involves balancing the benefit of preventing blood clots against the inherent risk of bleeding, and renal impairment can significantly shift this balance.
Contraindications
Dabigatran etexilate Olpha should not be used in the following situations:
- Severe renal impairment: Patients with creatinine clearance (CrCl) below 30 mL/min. Due to the predominantly renal elimination of dabigatran, severe kidney impairment leads to significantly elevated drug levels and an unacceptable bleeding risk.
- Active clinically significant bleeding: Patients with ongoing haemorrhage from any site, including gastrointestinal, intracranial, or urogenital bleeding.
- Hypersensitivity: Known allergy to dabigatran etexilate, dabigatran, or any of the excipients in the formulation.
- Severe hepatic disease: Liver disease associated with coagulopathy, or liver impairment expected to have a significant impact on survival. However, since dabigatran is not metabolised by the liver via CYP450 enzymes, mild-to-moderate hepatic impairment does not contraindicate its use.
- Prosthetic heart valves: The RE-ALIGN trial demonstrated an increased risk of thromboembolic and bleeding complications with dabigatran in patients with mechanical heart valves. Dabigatran is therefore contraindicated in this population. Warfarin remains the standard treatment.
- Concomitant treatment with strong P-glycoprotein inhibitors: Systemic ketoconazole, cyclosporine, itraconazole, and dronedarone are contraindicated with dabigatran due to significant increases in drug plasma levels.
- Lesions at risk of clinically significant bleeding: Such as current or recent gastrointestinal ulceration, malignant neoplasms at high risk of bleeding, recent brain or spinal surgery, or oesophageal varices.
Premature discontinuation of dabigatran without switching to an alternative anticoagulant increases the risk of thrombotic events, including stroke. If you need to stop dabigatran for surgery or other reasons, your doctor will provide specific guidance on when to stop and restart the medication. Never stop taking dabigatran without consulting your prescriber. The typical recommendation is to discontinue dabigatran 24–48 hours before elective surgery, depending on the bleeding risk of the procedure and kidney function.
Warnings and Precautions
Special caution is required when using dabigatran in the following situations:
- Renal function monitoring: Kidney function (creatinine clearance) must be assessed before starting treatment and should be re-evaluated at least annually in all patients. More frequent monitoring (every 3–6 months) is recommended in patients aged over 75, those with renal impairment, or in clinical situations that may reduce renal function (dehydration, concomitant nephrotoxic drugs, acute illness).
- Moderate renal impairment (CrCl 30–50 mL/min): Dose reduction is required. The half-life of dabigatran is significantly prolonged in this population (approximately 15–18 hours compared to 12–14 hours in normal renal function), leading to higher steady-state plasma concentrations.
- Increased bleeding risk: Conditions or concomitant medications that increase bleeding risk require careful evaluation. These include antiplatelet therapy, NSAID use, recent surgery, thrombocytopenia, active peptic ulcer disease, and disorders with impaired haemostasis.
- Gastrointestinal effects: Dyspepsia and gastrointestinal bleeding are more common with dabigatran than with warfarin. Taking the capsules with a full glass of water and with food may help reduce dyspepsia. Proton pump inhibitors (PPIs) may be used to manage symptoms without significantly affecting dabigatran absorption.
- Spinal or epidural anaesthesia: Patients receiving neuraxial anaesthesia or undergoing spinal/epidural puncture are at risk of epidural or spinal haematoma, which may result in long-term or permanent paralysis. Specific timing guidelines for discontinuation must be followed.
- Elderly patients (over 80 years): A reduced dose is generally recommended due to the age-related decline in renal function and the pharmacokinetic data showing higher exposure in older patients.
Pregnancy and Breastfeeding
There are limited data on the use of dabigatran during pregnancy. Animal studies have shown reproductive toxicity, including decreased foetal body weight and viability at high doses. As a precautionary measure, dabigatran is not recommended during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the foetus. Women of childbearing potential should use effective contraception during treatment.
It is not known whether dabigatran is excreted in human breast milk. Animal studies have shown excretion in milk. A decision must be made whether to discontinue breastfeeding or to discontinue dabigatran therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. As a precaution, breastfeeding should be discontinued during treatment with dabigatran.
Unlike other DOACs, dabigatran is predominantly renally eliminated (~80% unchanged). This makes kidney function the single most important safety parameter. Your doctor must check your creatinine clearance (CrCl) before starting treatment, at least annually during treatment, and whenever a clinical situation arises that may affect kidney function. Patients with CrCl <30 mL/min must not take dabigatran. Patients with CrCl 30–50 mL/min require dose reduction.
How Does Dabigatran etexilate Olpha Interact with Other Drugs?
Quick Answer: Dabigatran is a substrate of the efflux transporter P-glycoprotein (P-gp) but is not metabolised by cytochrome P450 enzymes. Strong P-gp inhibitors (ketoconazole, dronedarone, cyclosporine) are contraindicated as they significantly increase dabigatran levels. P-gp inducers (rifampicin, St John’s Wort) significantly decrease dabigatran levels and should be avoided. Concomitant anticoagulants, antiplatelet agents, and NSAIDs increase bleeding risk.
The drug interaction profile of dabigatran differs from that of factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) in an important way: dabigatran is not metabolised by cytochrome P450 enzymes. Instead, the prodrug dabigatran etexilate is converted to active dabigatran by plasma and hepatic esterases. However, dabigatran etexilate (but not dabigatran itself) is a substrate for the drug efflux transporter P-glycoprotein (P-gp). This means that drugs which inhibit or induce P-gp can significantly affect dabigatran plasma levels.
The absence of CYP450 metabolism means that dabigatran has fewer pharmacokinetic drug interactions than many other anticoagulants, including warfarin and the factor Xa inhibitors. However, P-gp interactions can be clinically very significant and must be carefully managed. Always inform your prescriber about all medications you are taking, including over-the-counter medicines, herbal supplements, and vitamins.
Major Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Ketoconazole (systemic) | Strong P-gp inhibitor; increases dabigatran levels by approximately 150% | Contraindicated – do not use together |
| Dronedarone | Strong P-gp inhibitor; increases dabigatran AUC by approximately 100% | Contraindicated – do not use together |
| Cyclosporine, itraconazole, tacrolimus | Strong P-gp inhibitors; expected to significantly increase dabigatran levels | Contraindicated – do not use together |
| Rifampicin | Strong P-gp inducer; decreases dabigatran AUC by approximately 66% | Avoid concomitant use; dabigatran efficacy is substantially reduced |
| Phenytoin, carbamazepine, phenobarbital | P-gp inducers; expected to significantly decrease dabigatran levels | Avoid concomitant use |
| St John’s Wort (Hypericum perforatum) | P-gp inducer; expected to decrease dabigatran levels | Avoid concomitant use |
| Other anticoagulants (heparin, warfarin, enoxaparin) | Additive anticoagulant effect; markedly increased bleeding risk | Avoid concomitant use except during transition between agents |
Minor Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Amiodarone | Moderate P-gp inhibitor; increases dabigatran AUC by approximately 50–60% | Consider dose reduction to 150 mg twice daily in AF patients; no adjustment needed for VTE prevention |
| Verapamil | Moderate P-gp inhibitor; increases dabigatran levels by 12–180% depending on timing and formulation | Reduce dabigatran dose; take dabigatran at least 2 hours before verapamil |
| Naproxen, ibuprofen, diclofenac (NSAIDs) | Do not alter dabigatran levels but independently increase bleeding risk, particularly gastrointestinal | Use with caution; avoid long-term concomitant use if possible |
| Aspirin (low dose) | Increases bleeding risk through additional antiplatelet effect | Use only when clinically indicated; shortest duration possible |
| Clopidogrel, ticagrelor, prasugrel | Antiplatelet agents; additive bleeding risk | Use only when clinically indicated; monitor for signs of bleeding |
| Proton pump inhibitors (omeprazole, pantoprazole) | May reduce dabigatran bioavailability by approximately 20–30% (not clinically significant) | No dose adjustment required; can be used to manage dabigatran-associated dyspepsia |
| SSRIs/SNRIs (fluoxetine, sertraline, venlafaxine) | May impair platelet function and increase bleeding risk | Use with caution; monitor for unusual bleeding |
Unlike warfarin, dabigatran does not have significant interactions with vitamin K-containing foods. You do not need to restrict your intake of green leafy vegetables, broccoli, or other vitamin K-rich foods. Dabigatran capsules can be taken with or without food, although taking them with food may help reduce the risk of dyspepsia. Food delays the time to peak plasma concentration by approximately 2 hours but does not significantly affect the total amount of drug absorbed (AUC).
What Is the Correct Dosage of Dabigatran etexilate Olpha?
Quick Answer: The standard dose varies by indication. For atrial fibrillation, the recommended dose is 150 mg twice daily, with a reduced dose of 110 mg twice daily for patients over 80 years or those at higher bleeding risk. For VTE prevention after surgery, the dose is 220 mg once daily (or 150 mg once daily in certain groups). Renal function determines all dosing decisions. Capsules must be swallowed whole.
Dabigatran dosing is more straightforward than warfarin dosing, as it uses fixed doses without INR-guided titration. However, dosing is significantly influenced by renal function, age, and the specific indication being treated. It is essential to take the dose prescribed by your doctor and not to adjust it yourself. Capsules must always be swallowed whole with a full glass of water – they must never be opened, crushed, or chewed, as this can increase bioavailability by up to 75% and lead to a dangerous increase in bleeding risk.
Adults
| Indication | Standard Dose | Reduced Dose | Duration |
|---|---|---|---|
| Stroke prevention in atrial fibrillation | 150 mg twice daily | 110 mg twice daily* | Long-term (indefinite) |
| Treatment of DVT/PE | 150 mg twice daily (after ≥5 days parenteral anticoagulant) | 110 mg twice daily in selected patients | At least 3–6 months |
| Prevention of recurrent DVT/PE | 150 mg twice daily | 110 mg twice daily in selected patients | Extended (based on individual risk-benefit assessment) |
| VTE prevention after hip replacement | 220 mg once daily (starting with 110 mg 1–4 hours post-surgery) | 150 mg once daily** | 28–35 days |
| VTE prevention after knee replacement | 220 mg once daily (starting with 110 mg 1–4 hours post-surgery) | 150 mg once daily** | 10 days |
*Dose reduction criteria for atrial fibrillation: A reduced dose of 110 mg twice daily is recommended for patients aged 80 years and over. It should also be considered for patients aged 75–80 years with additional bleeding risk factors, patients with moderate renal impairment (CrCl 30–50 mL/min), patients with gastritis, oesophagitis, or gastroesophageal reflux, and those at increased risk of bleeding. In patients taking concomitant verapamil, the dose should be reduced to 110 mg twice daily.
**Dose reduction for VTE prevention after surgery: A dose of 150 mg once daily (starting with 75 mg 1–4 hours post-surgery) is recommended for patients with moderate renal impairment (CrCl 30–50 mL/min) and patients aged 75 years and over.
Children
Dabigatran etexilate is approved for the treatment of VTE and prevention of VTE recurrence in paediatric patients in some markets. The dosing in children is weight-based, and paediatric formulations (oral pellets) are available for this purpose. However, Dabigatran etexilate Olpha capsules (75 mg) are designed for adult use. Paediatric dosing should only be initiated and managed by a specialist with experience in paediatric anticoagulation.
Elderly
Elderly patients require careful dose assessment due to the natural age-related decline in renal function. For patients aged 80 years and over with atrial fibrillation, the recommended dose is 110 mg twice daily. For patients aged 75–80, the standard 150 mg twice daily dose may be used, but consideration of the lower 110 mg twice daily dose is warranted if other risk factors for bleeding are present. The RE-LY trial included over 7,000 patients aged 75 and older, confirming that dabigatran maintained an acceptable efficacy and safety profile in this population, though the net clinical benefit was most favourable with the 110 mg dose in the very elderly.
Missed Dose
If you miss a dose of dabigatran, take it as soon as you remember, provided there are still 6 or more hours until the next scheduled dose. If fewer than 6 hours remain, skip the missed dose and take the next one at the regular time. Do not take a double dose to compensate for a missed dose. For the once-daily dosing regimen used for VTE prevention after surgery, a missed dose can be taken up to the time of the next scheduled dose. Missing doses increases the risk of blood clots, so it is important to take dabigatran as consistently as possible.
Overdose
In cases of overdose with dabigatran, specific management options are available. Idarucizumab (Praxbind) is the specific reversal agent for dabigatran and can fully reverse its anticoagulant effect within minutes. It is indicated for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding. Additionally, because dabigatran has low protein binding (~35%), it can be removed by haemodialysis – a unique advantage among DOACs. Activated charcoal administered within 2 hours of ingestion may also help reduce absorption. Treatment is otherwise supportive, with management of bleeding complications as they arise.
If you suspect an overdose of dabigatran, contact your local poison control centre or go to the nearest emergency department immediately. Symptoms of overdose may include unusual bleeding, blood in urine or stool, excessive bruising, or prolonged bleeding from cuts. The availability of idarucizumab and the option of haemodialysis provide specific tools for emergency management that are not available for most other anticoagulants. Do not attempt to induce vomiting unless instructed by a healthcare professional.
What Are the Side Effects of Dabigatran etexilate Olpha?
Quick Answer: The most common side effects of dabigatran are gastrointestinal symptoms (dyspepsia, nausea, abdominal pain) and bleeding-related events (nosebleeds, bruising, gastrointestinal haemorrhage). Dyspepsia is more common with dabigatran than with warfarin or other DOACs. Serious side effects include major bleeding events such as gastrointestinal haemorrhage and intracranial bleeding.
As with all anticoagulant medications, the primary risk associated with dabigatran is bleeding. The landmark RE-LY trial, which compared two doses of dabigatran (110 mg and 150 mg twice daily) with warfarin in over 18,000 patients with atrial fibrillation, provided the definitive safety data. Dabigatran 150 mg had a similar rate of major bleeding to warfarin (3.11% vs 3.36% per year) but a significantly lower rate of intracranial haemorrhage (0.30% vs 0.74% per year). Dabigatran 110 mg had a significantly lower rate of major bleeding (2.71% vs 3.36% per year). However, both dabigatran doses were associated with a higher rate of gastrointestinal bleeding than warfarin.
A distinctive feature of dabigatran compared to other DOACs is the higher incidence of dyspepsia (heartburn, stomach discomfort, nausea). This is attributed to the tartaric acid core of the dabigatran capsule formulation, which is necessary for adequate drug absorption. Taking capsules with food and a full glass of water can help minimise this side effect.
Common
Affects 1–10 in 100 patients
- Dyspepsia (heartburn, stomach discomfort, epigastric pain)
- Gastrointestinal haemorrhage (bleeding in the stomach or intestines)
- Abdominal pain
- Nausea
- Diarrhoea
- Epistaxis (nosebleeds)
- Urogenital bleeding (including haematuria)
- Bruising (ecchymosis, skin contusion)
- Anaemia (decreased haemoglobin)
Uncommon
Affects 1–10 in 1,000 patients
- Rectal bleeding
- Haemorrhoidal bleeding
- Gastrointestinal ulcer (with or without bleeding)
- Gastro-oesophagitis
- Gastro-oesophageal reflux disease
- Vomiting
- Dysphagia (difficulty swallowing)
- Haemoptysis (coughing up blood)
- Vaginal bleeding (abnormal)
- Eye haemorrhage (conjunctival)
- Skin bleeding (haematoma, petechiae)
- Allergic reactions (skin rash, pruritus, urticaria)
- Elevated liver enzymes (ALT, AST)
- Thrombocytopenia (low platelet count)
Rare
Affects 1–10 in 10,000 patients
- Intracranial haemorrhage (bleeding in the brain)
- Retroperitoneal haemorrhage
- Hepatic function abnormal / hepatitis
- Hypersensitivity reactions (angioedema, anaphylactic reaction)
- Bronchospasm
Very Rare / Post-marketing Reports
Affects fewer than 1 in 10,000 patients
- Alopecia (hair loss)
- Surgical site haemorrhage
- Severe or uncontrollable bleeding from any site
- Blood in vomit or vomit that looks like coffee grounds
- Black or tarry stools, or bright red blood in stool
- Pink or brown urine
- Sudden severe headache, confusion, vision changes, or weakness on one side (signs of intracranial bleeding)
- Signs of allergic reaction: swelling of face, lips, tongue or throat, difficulty breathing, severe skin rash
- Persistent severe abdominal pain
A key advantage of dabigatran over warfarin is the significantly lower rate of intracranial haemorrhage – the most feared complication of anticoagulation. A meta-analysis of DOAC trials (Ruff et al., The Lancet, 2014) confirmed that DOACs as a class reduce intracranial bleeding by approximately 52% compared to warfarin. The higher rate of gastrointestinal bleeding with dabigatran 150 mg compared to warfarin is an important consideration, particularly in elderly patients and those with a history of gastrointestinal disease, where the lower 110 mg dose may be more appropriate.
How Should You Store Dabigatran etexilate Olpha?
Quick Answer: Store dabigatran capsules at room temperature (below 30°C / 86°F) in the original packaging to protect from moisture. Keep out of reach of children. Once opened, blister packs should be used within 30 days. Do not use after the expiry date.
Proper storage of dabigatran capsules is particularly important because the formulation is sensitive to moisture. Exposure to moisture can affect drug stability and bioavailability. Dabigatran etexilate Olpha capsules should be stored according to the following guidelines:
- Temperature: Store at room temperature, not exceeding 30°C (86°F). Do not freeze.
- Moisture protection: This is critical for dabigatran capsules. Store in the original blister packaging until use. If the capsules are supplied in a bottle, keep the bottle tightly closed with the desiccant capsule inside to protect from moisture. Do not transfer capsules to a pill organiser or other container.
- After opening (blister packs): Once the blister pack is opened, capsules should be used within 30 days.
- After opening (bottles): Once a bottle is opened, capsules should be used within 4 months. Keep the desiccant inside the bottle.
- Children: Keep all medicines out of the sight and reach of children. Consider using a locked medicine cabinet.
- Expiry: Do not use dabigatran after the expiry date stated on the carton and blister/bottle. The expiry date refers to the last day of that month.
- Disposal: Do not throw away medicines via household waste or wastewater. Ask your pharmacist how to dispose of medicines you no longer need.
Dabigatran capsules contain a tartaric acid core that is essential for adequate drug absorption. This formulation is hygroscopic (absorbs moisture from the air). If capsules are exposed to excessive moisture, the drug may degrade, potentially affecting its efficacy. Always store capsules in their original packaging and never place them in a damp environment such as a bathroom cabinet near a shower.
What Does Dabigatran etexilate Olpha Contain?
Quick Answer: Each hard capsule contains 75 mg of dabigatran etexilate (as mesilate). The capsules also contain a tartaric acid core and inactive ingredients (excipients) that assist with manufacturing, stability, and drug absorption.
Understanding the composition of your medication can help identify potential allergens or excipients that may cause sensitivity. Dabigatran etexilate Olpha is a generic medication that contains the same active ingredient at the same strength as the originator product (Pradaxa), although certain excipients may differ between manufacturers.
Active Ingredient
- Dabigatran etexilate Olpha 75 mg: Each hard capsule contains 75 mg of dabigatran etexilate (as mesilate), equivalent to 68.18 mg dabigatran etexilate base.
Excipients (Inactive Ingredients)
The following excipients are typically present in dabigatran etexilate capsules:
- Capsule fill (tartaric acid pellets): Tartaric acid, acacia (gum arabic), hypromellose, dimeticone, talc, hydroxypropylcellulose. The tartaric acid core creates a local acidic microenvironment that is essential for the dissolution and absorption of dabigatran etexilate.
- Capsule shell: Carrageenan, potassium chloride, titanium dioxide (E171), hypromellose, purified water. The capsule may also contain iron oxide pigments (E172) depending on the manufacturer and dosage strength.
- Printing ink: Shellac, iron oxide black (E172), potassium hydroxide.
Dabigatran etexilate has pH-dependent solubility and requires an acidic environment for adequate dissolution. The tartaric acid pellets in the capsule formulation create a local acidic microenvironment in the stomach, independent of gastric pH. This is why the capsules must not be opened or crushed – the tartaric acid core is integral to proper drug absorption. Without it, bioavailability increases dramatically and unpredictably, which is why the tartaric acid also contributes to the dyspepsia commonly reported with dabigatran.
Capsule Appearance
- 75 mg capsules: The appearance may vary between manufacturers. Pradaxa 75 mg capsules are printed with the Boehringer Ingelheim logo and “R75”. Generic versions, including Dabigatran etexilate Olpha, may have a different appearance but contain the same active ingredient at the same strength.
Always verify the identity of your capsules with your pharmacist if you notice any changes in appearance when switching between manufacturers.
Frequently Asked Questions About Dabigatran etexilate Olpha
References
This article is based on the following peer-reviewed sources, international guidelines, and regulatory documents:
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RE-LY). N Engl J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa0905561
- Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER). N Engl J Med. 2009;361(24):2342–2352. doi:10.1056/NEJMoa0906598
- Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement (RE-NOVATE). Lancet. 2007;370(9591):949–956. doi:10.1016/S0140-6736(07)61445-7
- Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis (RE-VERSE AD). N Engl J Med. 2017;377(5):431–441. doi:10.1056/NEJMoa1707278
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi:10.1016/S0140-6736(13)62343-0
- European Society of Cardiology. 2024 ESC/EACTS Guidelines for the Management of Atrial Fibrillation. Eur Heart J. 2024. doi:10.1093/eurheartj/ehae176
- January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation. J Am Coll Cardiol. 2019;74(1):104–132.
- European Medicines Agency. Pradaxa (dabigatran etexilate) – Summary of Product Characteristics. EMA, 2024. EMA – Pradaxa
- U.S. Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate) – Prescribing Information. FDA, 2024.
- British National Formulary. Dabigatran etexilate. BNF, 2025. BNF – Dabigatran etexilate
- World Health Organization. WHO Model List of Essential Medicines – 23rd List. WHO, 2023.
- Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves (RE-ALIGN). N Engl J Med. 2013;369(13):1206–1214. doi:10.1056/NEJMoa1300615
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians specialising in clinical pharmacology, haematology, and internal medicine.
iMedic Medical Editorial Team – specialists in clinical pharmacology and anticoagulation therapy with extensive experience in evidence-based medical communication.
iMedic Medical Review Board – independent panel of medical experts who verify all content against current international guidelines (ESC, AHA/ACC, EMA, FDA, BNF, WHO).
All iMedic content follows the GRADE evidence framework and is based on Level 1A evidence (systematic reviews of randomised controlled trials) where available. We have no commercial funding or pharmaceutical sponsorship. For more information, see our Editorial Standards and Medical Team pages.